Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Stockholders held by Aclaris Therapeutics, Inc. on June 29, 2016. The filing details the results of two proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 20,316,923 shares outstanding as of the record date, 18,387,947 shares (90.5%) were present or represented by proxy. The results for the proposals were as follows:
- Proposal No. 1 (Election of Directors): Two nominees were elected to serve until the 2019 annual meeting.
- Neal Walker: 16,382,358 votes For; 682,092 votes Withheld.
- Albert Cha, M.D., Ph.D.: 16,302,663 votes For; 761,787 votes Withheld.
- Broker Non-Votes: 1,323,497.
- Proposal No. 2 (Ratification of Auditors): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016, was ratified unanimously.
- Votes For: 18,387,947
- Votes Against: 0
- Abstained: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Neal Walker and Albert Cha, M.D., Ph.D., were successfully elected to the Board of Directors.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for the 2016 fiscal year with no votes against.
- Shareholder participation was high, with 90.5% of outstanding shares represented at the meeting.
- There were 1,323,497 broker non-votes recorded for the director election proposal.